Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02903940 · ClinicalTrials.gov registry record
The Application of Negative Atrioventricular Hysteresis in Cardiac Resynchronization Therapy
A clinical trial, sponsored by Abbott Medical Devices.
- Completed
- Registry status
- 30
- Enrollment target
NCT02903940: Completed study, sponsored by Abbott Medical Devices.
NCT02903940 is a clinical trial that has completed, run by Abbott Medical Devices. The registered enrollment target is 30 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02903940 has completed, sponsored by Abbott Medical Devices.
- COMPLETED
- Registry status
- 30 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the application of Negative Atrioventricular Hysteresis (NAVH) to improve electrical synchrony in Cardiac Resynchronization Therapy (CRT) patients.
Interventions
- DEVICE CRT+NAVH
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2016-12 |
| Est. Completion | 2022-12 |
What the finished NCT02903940 record still lists
NCT02903940 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 30 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which CRT+NAVH is the first listed.
NCT02903940 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02903940 about?
NCT02903940 is a clinical study titled "The Application of Negative Atrioventricular Hysteresis in Cardiac Resynchronization Therapy". The purpose of this study is to evaluate the application of Negative Atrioventricular Hysteresis (NAVH) to improve electrical synchrony in Cardiac Resynchronization Therapy (CRT) patients.
What is the current status of trial NCT02903940?
This trial is currently completed. The enrollment target is 30 participants. The study started on 2016-12. Estimated completion is 2022-12.
What interventions are being tested in trial NCT02903940?
The interventions under investigation include: CRT+NAVH (DEVICE).
Who is sponsoring clinical trial NCT02903940?
This trial is sponsored by Abbott Medical Devices, which has 261 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia